What is Contamination Control by Design™ (CCbD™) and why does it matter?
- 2 hours ago
- 5 min read
In August 2022, the European Medicines Agency published the revised EU GMP Annex 1 on the manufacture of sterile medicinal products. The revision introduced one of the most significant documentation requirements the industry had seen in years: every sterile manufacturing site must develop and maintain a documented, risk-based Contamination Control Strategy (CCS).
The requirement was clear. The path to meeting it was not.
Most sites reached for what they knew: Word documents, Excel risk registers, and a flurry of consultants each building something slightly different. The result was CCS documents that looked different at every site, lacked linkage between risk assessments and controls, had no traceability, and could not survive sustained inspection scrutiny.
That is the problem Contamination Control by Design was built to solve.
The gap in the market
Before CCbD™, there was no standardised methodology for building a CCS. Sites either engaged consultants who applied their own bespoke approach, or they built from scratch internally with varying levels of expertise and no validated regulatory reference point.
The consequences were predictable. Contamination risk assessments missed entire categories of risk. Design controls were not linked back to documented risk justifications. Qualification activities were not traceable to the specific risks they were designed to verify. And when inspectors arrived and asked for the thread between risk and control, it simply was not there.
The absence of a validated, regulatory-mapped starting point creates systematic gaps in every CCS built without one. These gaps are invisible until an inspector finds them.
Pharmalliance developed the CCbD™ framework to close those gaps, and built the CCbD™ Platform to deliver that framework at scale, repeatably, and with full audit traceability built in from day one.
What is CCbD™?
Contamination Control by Design (CCbD) is a structured, lifecycle-integrated methodology for developing and maintaining a fully Annex 1-compliant CCS. It is built on a core principle that contamination control must be embedded at the design stage, not bolted on as a documentation exercise before inspection.
CCbD™ is not a template. It is a framework that guides manufacturing sites through systematic risk identification, pathway analysis, design specification, qualification planning, operational monitoring, and ongoing governance. The output is a complete, audit-ready CCS master document and a connected set of supporting deliverables, all traceable back to the risk evidence that generated them.
The CCbD™ Standard is freely available for download. The CCbD™ Platform is the SaaS implementation that makes it repeatable, scalable, and inspection-ready.
How it works: six structured steps
The CCbD™ workflow moves a site from facility concept through to ongoing governance across six connected stages. Each stage gates the next. A step cannot be closed without resolving identified gaps.
Who benefits, and how
Sterile manufacturers and CDMOs get a structured, repeatable process that eliminates the blank page problem. The platform risk library is seeded with over 100 curated contamination risks, mapped to Annex 1, ICH Q9(R1), and applicable pharmacopoeial standards. Sites are not starting from nothing. They are starting from a validated, regulatory-mapped reference set and building from there.
Quality and regulatory affairs teams get full traceability from risk through control through verification. The thread that inspectors look for is built into the platform architecture, not constructed after the fact. Every design control has a documented risk justification. Every monitoring point has a risk basis. The CCS master document is generated from the live data, not assembled manually.
Engineering and facilities teams get a design specification grounded in documented contamination risk, not generic engineering standards. Qualification plans are generated from the design controls. Activities are traceable to the specific risks they are designed to verify.
Regulators see a CCS that is structured, cross-referenced to Annex 1 requirements, and backed by documented risk evidence. The scoring methodology is transparent. Risk acceptance is formally recorded. Annual governance reviews are built into the workflow with dual sign-off by QA Director and Site Director.
And patients benefit from medicines manufactured in facilities where contamination risks have been systematically identified, eliminated by design where possible, and continuously monitored against a risk-based baseline. That is what a well-built CCS delivers. CCbD™ is how you build it.
How does it work?
Every project starts with a single dashboard view. Progress across all six steps is visible at a glance, with compliance status flags surfacing gaps before they become inspection findings.
The risk register is the foundation of everything. Each risk is scored across probability, severity, and detectability, cross-referenced to the relevant Annex 1 clause, and linked forward to the design controls that address it. HIGH and CRITICAL risks cannot be progressed without a documented control in place.
Users step through the 6 step process with ease, building confidence that their facilities is built with Contamination Control best practices built in from the start. At the end of each step their is a defined deliverable available for download and approval in your QMS. Progress is gated to ensure that adequate design control, qualification, operational and monitoring and governance is in place prior to completion.
At the end of the process you have a complete pre-populated Contamination Control Strategy, aligned fully with EU Annex 1 and ready for approval.
What about ongoing Governance?
Governance does not stop at go-live. Step 06 gives QA teams a live view of KPI status, a rolling 12-month EM excursion tracker, deviation and CAPA linkage, and the annual CCS review certification workflow. Inspection readiness becomes a continuous state, not a pre-inspection sprint.
Built for CDMOs and multi-site organisations
CDMOs face a compounding challenge: multiple clients, multiple product types, and facilities that may serve both sterile and non-sterile operations. A single approach fails here.
CCbD™ supports three manufacturing modalities: Sterile Manufacturing, Bioburden Controlled, and Non-Sterile GMP. Each has a calibrated risk library, appropriate scoring logic, and modality-specific compliance mapping. A CDMO can run independent CCS projects for different client programmes, with appropriate isolation and governance, within the same platform.
Download the CCbD™ Standard
The CCbD™ Standard is freely available. It defines the full framework methodology, regulatory basis, scoring approach, and deliverable architecture. Download it, apply it, and see what a structured CCS looks like. The CCbD Standard can be downloaded for free at www.ccbd.io or click below.
We have released the Foundation level of our CCbD training level, in it it outlines what CCbD is all about and how you can incorporate it into your operation. Click the link below to find out more, it is currently 50% off.
Pharmalliance Consulting Ltd specialises in cGMP Compliance, Remediation and Contamination Control. We have always helped companies build audit ready Contamination Control programs, the CCbD program now builds on that expertise and offers true compliance linkage, keeping you audit ready, always.
© 2026 Pharmalliance Consulting Ltd. All rights reserved. CCbD™ and Contamination Control by Design™ are trademark applications of Pharmalliance Consulting Ltd. EUIPO application nos. 019328252 and 019328176. USPTO applications 390956 and 390964. Use of ™ pending registration confirmation.
Comments